Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday

Estrella Immunopharma (NASDAQ:ESLA) is anticipated to post its results before the market opens on Wednesday, May 13th. Analysts expect Estrella Immunopharma to post earnings of ($0.0840) per share for the quarter.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings results on Wednesday, March 18th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.17. On average, analysts expect Estrella Immunopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Estrella Immunopharma Price Performance

ESLA opened at $1.41 on Wednesday. The company has a market capitalization of $60.02 million, a price-to-earnings ratio of -4.02 and a beta of 0.97. The firm’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.55. Estrella Immunopharma has a 1 year low of $0.78 and a 1 year high of $3.15.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $8.00 price objective on shares of Estrella Immunopharma in a report on Monday, February 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Estrella Immunopharma currently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On Estrella Immunopharma

Hedge funds have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new stake in shares of Estrella Immunopharma during the 4th quarter worth $43,000. State Street Corp raised its stake in shares of Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares during the period. XTX Topco Ltd raised its stake in shares of Estrella Immunopharma by 376.9% during the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the period. Marshall Wace LLP bought a new stake in shares of Estrella Immunopharma during the 4th quarter worth $88,000. Finally, Geode Capital Management LLC raised its stake in shares of Estrella Immunopharma by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares during the period. 0.35% of the stock is currently owned by institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.